vimarsana.com

Page 21 - புதியது ப்ராடக்ட்ஸ் மற்றும் சேவைகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Altra Industrial Motion Corp to Host Conference Call on First Quarter 2021 Financial Results

Cresco Labs Expands Branded Edibles Portfolio With Launch of Wonder Wellness Gummies

Press release content from Business Wire. The AP news staff was not involved in its creation. Cresco Labs Expands Branded Edibles Portfolio With Launch of Wonder Wellness Gummies April 12, 2021 GMT Cresco Labs launched a new line of effect-forward, low-dose gummies enhanced with botanicals under its Wonder Wellness brand. (Photo: Business Wire) Cresco Labs launched a new line of effect-forward, low-dose gummies enhanced with botanicals under its Wonder Wellness brand. (Photo: Business Wire) CHICAGO (BUSINESS WIRE) Apr 12, 2021 Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, today announced the launch of Wonder Wellness (“Wonder”) Gummies and availability in Illinois. The new low-dose edibles are enhanced with botanicals to complement the overall cannabis experience, and their simple packaging communicates desired effects so wellness-mind

LG Energy Solution and SK Innovation Reach Agreement to End USITC Trade Secret Dispute and End Litigation

Biden sees `win for US in electric vehicle battery deal

BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021

Press release content from Business Wire. The AP news staff was not involved in its creation. BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021 April 11, 2021 GMT CAMBRIDGE, Mass. & BEIJING (BUSINESS WIRE) Apr 11, 2021 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical data on its anti-PD-1 antibody tislelizumab, in combination with the investigational spectrum-selective kinase inhibitor sitravatinib being jointly developed with Mirati Therapeutics, Inc. (Mirati), were presented in two oral presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021. Data presented at the meeting were from two cohorts of a Phase 1b trial (NCT03666143), in patients with unresectable or metastatic melanoma who were refractory or resistant to PD-1/L1 inhibitors and in patien

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.